Chinese Journal of Tissue Engineering Research ›› 2012, Vol. 16 ›› Issue (12): 2125-2128.doi: 10.3969/j.issn.1673-8225.2012.12.008

Previous Articles     Next Articles

Effects of chitosan-coated levodopa nanoliposomes on behaviour and levels of phosphorylated Mr 32 000 dopamine- and cyclic adenosine monophosphate-regulated phosphoprotein in rats with dyskinesia 

Wang Lei, Yan Dan, Xiao Hai-bing, Sun Sheng-gang, Xu Yan   

  1. Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan  430022, Hubei Province, China
  • Received:2011-09-14 Revised:2011-12-27 Online:2012-03-18 Published:2012-03-18
  • Contact: author: Xu Yan, Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China yan.xu@emory.edu
  • About author:Wang Lei☆, Studying for doctorate, Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China dr.wanglei@qq.com
  • Supported by:

    the National Natural Science Foundation of China, No. 30700881*

PDF

548

Abstract:

BACKGROUND: Levodopa is the main drug for treatment of Parkinson's disease, but most patients suffer from levodopa- induced dyskinesias after a long-term administration.
OBJECTIVE: To study the effect of chitosan-coated levodopa nanoliposomes on behavioral characters and levels of phosphorylated Mr 32 000 dopamine- and cyclic adenosine monophosphate-regulated phosphoprotein (DARPP-32) in the striatum of rat models of levodopa-induced dyskinesia.
METHODS: Unilateral 6-hydroxydopamine lesioned rat models of Parkinson’s disease were established in 25 rats and divided into three groups treated separately with chitosan-coated levodopa nanoliposomes (liposome group, n=10), carbidopa and levodopa (levodopa group, n=10), and normal saline (control group, n=5) once daily for 4 weeks.
RESULTS AND CONCLUSION: Levels of phospho-Thr34 DARPP-32 in the striatum and scores of abnormal involuntary movement increased significantly in the levodopa group (P < 0.05) and liposome group (P < 0.05) compared with the control group. However in the liposome group, the expression of phospho-Thr34 DARPP-32 in the striatum decreased compared with the levodopa group, scores of abnormal involuntary movement decreased also, and the differences between them were significant  (P < 0.05). Chitosan-coated levodopa nanoliposomes may be useful in the prevention and treatment of dyskinesias to parkinsonian patients.

CLC Number: